Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Macroalbuminuria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Macroalbuminuria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-001348-24 Sponsor Protocol Number: 3004 Start Date*: 2012-09-10
    Sponsor Name:Joslin Diabetes Center
    Full Title: A pilot study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003481-14 Sponsor Protocol Number: 3004 Start Date*: 2014-03-07
    Sponsor Name:National Institute of Diabetes and Digestive and Kidney Diseases
    Full Title: Study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004848 10037827 Raised serum uric acid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006191-38 Sponsor Protocol Number: 004SC06084 Start Date*: 2007-01-11
    Sponsor Name:ANGELINI
    Full Title: The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study.
    Medical condition: Patients with type II diabetes with nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047065 Vascular disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-000452-14 Sponsor Protocol Number: FARM537JNE Start Date*: 2007-08-29
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Long term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A...
    Medical condition: Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027525 Microalbuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002603-17 Sponsor Protocol Number: 1218.89 Start Date*: 2013-01-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin ...
    Medical condition: Type 2 diabetes patients receiving treatment with ACEi or ARB with micro- or macroalbuminuria (UACR between 30 and 3000 mg/g creatinine). [ACEi=Angiotensin Converting Enzyme inhibitor; ARB=Angioten...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004494-28 Sponsor Protocol Number: 28431754DNE3001 Start Date*: 2014-07-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Di...
    Medical condition: Type 2 Diabetes Mellitus and Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IT (Completed) HU (Completed) DE (Completed) BG (Completed) ES (Completed) PL (Completed) LT (Completed) SK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002644-32 Sponsor Protocol Number: EFC14875 Start Date*: 2017-11-14
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Ca...
    Medical condition: Type 2 diabetes mellitus Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LV (Completed) GB (Completed) HU (Completed) SE (Completed) NO (Completed) FR (Completed) NL (Completed) DK (Completed) ES (Prematurely Ended) LT (Completed) EE (Completed) PT (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-003636-88 Sponsor Protocol Number: KBP5074-3-001 Start Date*: 2022-07-12
    Sponsor Name:KBP BioSciences PTE. Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hype...
    Medical condition: Uncontrolled hypertension in patients who have Stage 3b/4 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066860 Uncontrolled hypertension LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended) LT (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000860-25 Sponsor Protocol Number: CSPP100E2337 Start Date*: 2007-07-27
    Sponsor Name:Novartis Farmacéutica, SA
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg...
    Medical condition: Diabetes tipo 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005093-54 Sponsor Protocol Number: CV202-010 Start Date*: 2013-05-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Twostage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic...
    Medical condition: Diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002077-31 Sponsor Protocol Number: RIMON_L_01814 Start Date*: 2008-09-09
    Sponsor Name:SANOFI-AVENTIS S.P.A
    Full Title: Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. ...
    Medical condition: Abdominal obese patients with type 2 diabetes mellitus and microalbuminuria.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000452-34 Sponsor Protocol Number: 3004 Start Date*: 2013-11-19
    Sponsor Name:Steno Diabetes Center
    Full Title: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria
    Medical condition: Patients with type 2 diabetes mellitus and normoalbuminuria
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000595-42 Sponsor Protocol Number: ESR-18-13834 Start Date*: 2019-07-08
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: A randomized, double-blind, placebo controlled, parallel, multicentre study of the effects of 12-weeks of sodium zirconium cyclosilicate (Lokelma) on albuminuria (UACR) in patients with diabetes an...
    Medical condition: Treatment for proteinuria in type 1 or type 2 diabetes with hyperkalemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005044-27 Sponsor Protocol Number: CVAL489AES15 Start Date*: 2005-04-01
    Sponsor Name:Luis Miguel Ruilope Urioste
    Full Title: COMPARATIVE, RANDOMIZED, OPEN, MULTICENTER TRIAL ASSESING THE EFFECT ON ALBUMIN EXCRETION RATE OF 320 MG. VALSARTAN (WITH OR WITHOUT HYDROCHLOROTHIAZIDE) vs. 40 MG. LISINOPRIL (WITH OR WITHOUT HYD...
    Medical condition: HYPERTENSIVE PATIENTS WITH DIABETIC AND NON DIABETIC CHRONIC NEPHROPATHY WITH AN ALBUMIN EXCRETION RATE >= 20 MG/GR CREATININE (20mg/24h) AND <= 1000 MG/GR CREATININE (1000mg/24h).
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029151 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005142-21 Sponsor Protocol Number: MLN1202-2005 Start Date*: 2015-05-20
    Sponsor Name:Takeda Development Centre Europe Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Su...
    Medical condition: Diabetic Nephropathy: Adults (age 18 - 90 years inclusive) with type 2 diabetes, an eGFR of 25-59 mL/min/1.73 m2, and with macroalbuminuria (>300 mg/g) will be randomized.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002676-24 Sponsor Protocol Number: D1690C00023 Start Date*: 2015-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: An exploratory Phase II/III, randomized, double-blind, placebo controlled, parallel design study to evaluate the efficacy, safety and pharmacodynamics of dapagliflozin and dapagliflozin in combinat...
    Medical condition: CKD3 patients with type 2 diabetes mellitus and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004726-10 Sponsor Protocol Number: AMR-01-01-0019 Start Date*: 2012-05-02
    Sponsor Name:Amarin Pharma Inc.
    Full Title: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patie...
    Medical condition: Cardiovascular Disease or at High Risk for Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002951-33 Sponsor Protocol Number: RIMON_L_01031 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis, S.A.
    Full Title: A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with abdominal obesity and microalbuminuria...
    Medical condition: Patients with abdominal obesity, with type 2 diabetes mellitus or dyslipidaemia, with or without other cardiometabolic risk factors.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10059179 Abdominal obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 16:11:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA